Simple jQuery Dropdowns
Please use this identifier to cite or link to this item:
Title: Model evaluation of target product profiles of an infant vaccine against respiratory syncytial virus (RSV) in a developed country setting
Authors: Timothy Kinyanjui
Wirichada Pan-Ngum
Sompob Saralamba
Sylvia Taylor
Lisa White
D. James Nokes
GlaxoSmithKline Pharmaceuticals SA/NV
Wellcome Trust Research Laboratories Nairobi
The University of Warwick
Mahidol University
Nuffield Department of Clinical Medicine
University of Manchester
Peak AI
Keywords: Biochemistry, Genetics and Molecular Biology;Immunology and Microbiology;Medicine;Veterinary
Issue Date: 9-Apr-2020
Citation: Vaccine: X. Vol.4, (2020)
Abstract: © 2020 The Author(s) Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract disease in children worldwide and is a significant cause of hospital admissions in young children in England. No RSV vaccine has been licensed but a number are under development. In this work, we present two structurally distinct mathematical models, parameterized using RSV data from the UK, which have been used to explore the effect of introducing an RSV paediatric vaccine to the National programme. We have explored different vaccine properties, and dosing regimens combined with a range of implementation strategies for RSV control. The results suggest that vaccine properties that confer indirect protection have the greatest effect in reducing the burden of disease in children under 5 years. The findings are reinforced by the concurrence of predictions from the two models with very different epidemiological structure. The approach described has general application in evaluating vaccine target product profiles.
ISSN: 25901362
Appears in Collections:Scopus 2020

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.